Abstract
Background: Age-related macular degeneration (AMD) is a condition that accounts for 75% of cases of legal blindness in individuals over the age of 50. Objectives: The objective of this review has been to evaluate the clinical effectiveness of available combined treatments modalities in the treatment of neovascular AMD. Data Sources: Central and Medline were searched for original research studies (Phase I, II, III), abstracts, and review articles concerning combination therapies for the control of neovascular AMD. We included randomized controlled trials (RCTs). Results: The results of therapeutic trials focused on the actual options in the management of neovascular AMD are discussed. Intravitreal treatment with substances targeting all isotypes of vascular endothelial growth factor (VEGF) results in a significant increase in visual acuity in patients with neovascular AMD. The combination with occlusive therapies like verteporfin photodynamic therapy (V-PDT) potentially offers a reduction of re-treatment frequency rate and long-term maintenance of the benefit reached. Despite the promise from combining anti-VEGF therapies with V-PDT, other combinations to improve outcomes with V-PDT deserve attention. Corticosteroids demonstrated an antiangiogenic effect and targeted the extravascular components of CNV, such as inflammatory cells and fibrocytes. Nevertheless, the study on the clinical application of corticosteroids will require a better understanding of the potential complications. Further developments interacting with various steps in the angiogenic cascade are under clinical or preclinical evaluation and may soon become available. In AMD the goal of a combination regimen is to address the therapy toward neovascular, inflammatory, and proliferative components of the disease. Conclusions: Combined treatments strategies are an obvious step providing disease control when it is not achieved with a single therapeutic approach. One risk of using a single therapy to control AMD is a rebound induced by compensatory stimulation of other pathogenetic pathways. Combination therapy is a logical approach to address mechanisms of disease progression that appear to be self-sustaining once initiated.
Keywords: Choroidal neovascularisation (CNV), age related macular degeneration (AMD), retinal degeneration, vascular endothelial growth factor (VEGF), verteporfin photodynamic therapy (V-PDT), anti-angiogenic therapies, combined therapies, isotypes, visual acuity, occlusive therapies, Corticosteroids, inflammatory cells, fibrocytes, Ranibizumab, bevacizumab, pegaptanib, stroke, myocardial infarction, MARINA, ANCHOR, immunosuppressants, rapamycin, hypoxia, steroids, attenuation
Current Drug Targets
Title: Combined Treatment Modalities for Age Related Macular Degeneration
Volume: 12 Issue: 2
Author(s): R. A. Das, A. Romano, F. Chiosi, M. Menzione and M. Rinaldi
Affiliation:
Keywords: Choroidal neovascularisation (CNV), age related macular degeneration (AMD), retinal degeneration, vascular endothelial growth factor (VEGF), verteporfin photodynamic therapy (V-PDT), anti-angiogenic therapies, combined therapies, isotypes, visual acuity, occlusive therapies, Corticosteroids, inflammatory cells, fibrocytes, Ranibizumab, bevacizumab, pegaptanib, stroke, myocardial infarction, MARINA, ANCHOR, immunosuppressants, rapamycin, hypoxia, steroids, attenuation
Abstract: Background: Age-related macular degeneration (AMD) is a condition that accounts for 75% of cases of legal blindness in individuals over the age of 50. Objectives: The objective of this review has been to evaluate the clinical effectiveness of available combined treatments modalities in the treatment of neovascular AMD. Data Sources: Central and Medline were searched for original research studies (Phase I, II, III), abstracts, and review articles concerning combination therapies for the control of neovascular AMD. We included randomized controlled trials (RCTs). Results: The results of therapeutic trials focused on the actual options in the management of neovascular AMD are discussed. Intravitreal treatment with substances targeting all isotypes of vascular endothelial growth factor (VEGF) results in a significant increase in visual acuity in patients with neovascular AMD. The combination with occlusive therapies like verteporfin photodynamic therapy (V-PDT) potentially offers a reduction of re-treatment frequency rate and long-term maintenance of the benefit reached. Despite the promise from combining anti-VEGF therapies with V-PDT, other combinations to improve outcomes with V-PDT deserve attention. Corticosteroids demonstrated an antiangiogenic effect and targeted the extravascular components of CNV, such as inflammatory cells and fibrocytes. Nevertheless, the study on the clinical application of corticosteroids will require a better understanding of the potential complications. Further developments interacting with various steps in the angiogenic cascade are under clinical or preclinical evaluation and may soon become available. In AMD the goal of a combination regimen is to address the therapy toward neovascular, inflammatory, and proliferative components of the disease. Conclusions: Combined treatments strategies are an obvious step providing disease control when it is not achieved with a single therapeutic approach. One risk of using a single therapy to control AMD is a rebound induced by compensatory stimulation of other pathogenetic pathways. Combination therapy is a logical approach to address mechanisms of disease progression that appear to be self-sustaining once initiated.
Export Options
About this article
Cite this article as:
A. Das R., Romano A., Chiosi F., Menzione M. and Rinaldi M., Combined Treatment Modalities for Age Related Macular Degeneration, Current Drug Targets 2011; 12 (2) . https://dx.doi.org/10.2174/138945011794182719
DOI https://dx.doi.org/10.2174/138945011794182719 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Related Books

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents, Formulation and Characterization of Nanoliposomes
Recent Patents on Drug Delivery & Formulation Immunosuppressive and Antiviral Treatment of Inflammatory Cardiomyopathy
Recent Patents on Cardiovascular Drug Discovery Determination of Aliskiren Hemifumarate and Amlodipine Besylate in their combined Dosage form by Different Spectrophotometric Methods
Current Pharmaceutical Analysis Depressive Illness and Emotional Learning
Current Medical Imaging Cardiovascular Morbidity and Mortality in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Treatment of Chronic Articular Pain in Adult People with Hemophilia
Cardiovascular & Hematological Disorders-Drug Targets Skeletal Muscle in Cancer Cachexia: The Ideal Target of Drug Therapy
Current Cancer Drug Targets Interactions between Inflammation and Coagulation in Autoimmune and Immune-Mediated Skin Diseases
Current Vascular Pharmacology Anticancer Properties of Amino Acid and Peptide Derivatives of Mycophenolic Acid
Anti-Cancer Agents in Medicinal Chemistry Self-Propelled Particles with Rotationally Asymmetric Shape
Current Physical Chemistry Recent Advances in Perioperative Anesthetic Management Update in the Perioperative Support of Patients with Septic Shock and the Effect on Outcomes
Current Pharmaceutical Design Androgen Deficiency in Aging Male Questionnaire for the Clinical Detection of Testosterone Deficiency in a Population of Black Sub-Saharan African Men with Type 2 Diabetes Mellitus: Is it a Reliable Tool?
Current Diabetes Reviews Assessment of the Impact of Flavoring on the Nutritional Content of Potato Chips
Current Nutrition & Food Science Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Human Galectin-3 Selective and High Affinity Inhibitors. Present State and Future Perspectives
Current Medicinal Chemistry Coumarin and Derivates as Lipid Lowering Agents
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Disorders of Consciousness: Recent Advances in Neurobiology and Treatments)
Current Pharmaceutical Design Visit-to-visit blood pressure variability and classes of antihypertensive agents; associations with artery remodeling and the risk of stroke
Current Pharmaceutical Design Is there Sex-related Outcome Difference According to oral P2Y12 Inhibitors in Patients with Acute Coronary Syndromes? A Systematic Review and Meta-Analysis of 107,126 Patients
Current Vascular Pharmacology Editorial [Hot Topic: Gliomas: Current Issues in Diagnosis and Treatment (Guest Editor: Stephan Ulmer)]
Current Medical Imaging